Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 14/20 | 0.43 |
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | IDE | P14735 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699568 | 0.92 | MDM2 (0.43) | MDM2MEN1IDEKMT2APDE4B | |
| SCHEMBL13699559 | 0.88 | CNR1 (0.42) | MDM2SMOMEN1IDEKMT2A | |
| SCHEMBL13699561 | 0.85 | MDM2 (0.45) | MDM2MEN1IDEKMT2A | |
| SCHEMBL13699562 | 0.84 | MDM2 (0.44) | MDM2MEN1IDEKMT2A | |
| SCHEMBL13699629 | 0.82 | MDM2 (0.40) | MDM2SMOMEN1IDEKMT2A | |
| SCHEMBL4163914 | 0.80 | MDM2 (0.46) | MDM2MEN1IDEKMT2A | |
| SCHEMBL4166201 | 0.80 | MDM2 (0.47) | MDM2MEN1IDEKMT2A | |
| SCHEMBL4166206 | 0.80 | MDM2 (0.47) | MDM2MEN1IDEKMT2A | |
| SCHEMBL4168355 | 0.79 | MDM2 (0.43) | MDM2MEN1IDEKMT2A | |
| SCHEMBL4168350 | 0.79 | MDM2 (0.43) | MDM2MEN1IDEKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
| WO-2007057687-A1 | PIPERAZINE DERIVATIVES AND THEIR USE IN THERAPY | VERNALIS (R & D) LIMITED (GB) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | CNR2, CNR1, ALK | MDM2 2997/4885SMO 161/4885MEN1 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.